Nexalin Technology (NXL) announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies, a leading Israeli medical device distributor, to market and sell Nexalin’s Gen-2 Console, 15 milliamp, non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin’s Gen-2 SYNC device in Israel for the treatment of a variety of mental health disorders
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin Technology announces FDA acceptance of Q-Sub for Gen-2 SYNC
- Nexalin Technology announces regulatory approval to sell Gen 2 SYNC
- Nexalin announces three studies published on Gen-2 Nexalin DIFS technology
- Nexalin Technology Amends Equity Distribution Agreement
- Nexalin Technology appoints Robert Rothstein to Scientific Advisory Board